TTTECH has appointed Eddie Myers as CEO of TTTECH North America Inc., effective July 15, 2026, to lead growth in aerospace, defense, and critical infrastructure sectors. Myers brings over 20 years of leadership experience from L3Harris Technologies and will focus on expanding TTTECH's presence in aviation, space, and defense markets. This move aims to strengthen TTTECH's innovation and partnerships with major industry players like NASA and Collins Aerospace. Myers looks forward to advancing TTTECH's strategy and customer relations at upcoming industry events.
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
KeyCorp is set to report earnings with analysts forecasting a 20% increase in earnings per share to $0.42 and an 8% rise in total revenue to $1.97 billion. The growth is mainly driven by a 10% increase in net interest income, fueled by strong commerc...
Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. ...
Shares of Zhengye Biotechnology surged over 1047% to regain Nasdaq compliance after a minimum bid price warning. Advanced Biomed and Axe Compute also saw notable gains following a reverse stock split and Russell Microcap Index inclusion, respectively...
